not really - look at CUV balance sheet and cash on hand plus revenue generated the market is selling that down BOT has no chance at higher valuation.
like I said biotech is not the space to be in when we are in the depths of a commodity super cycle, hence why all biotechs are getting sold off.
If super cycle is correct yoi could be stuck in bios for 2 years or so before a change of trend, might go all the way down to teens and base around there for several years before money flow back to bios.
DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $578.4M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $3.745M | 12.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 334744 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 93939 | 4 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |